Epidermal growth factor receptor (EGFR) mutations represent one of the most common actionable oncogenic drivers in non–small cell lung cancer (NSCLC), affecting approximately 10-15% of patients with advanced disease in Western countries and up to 40–50% in Asia (1). The gene discussed is EGFR; the disease is lung cancer.